Silence Therapeutics (SLN)
(Delayed Data from NSDQ)
$21.74 USD
+0.32 (1.49%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $21.74 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLN 21.74 +0.32(1.49%)
Will SLN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SLN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLN
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
SLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?
Other News for SLN
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Silence Therapeutics (SLN) and Exscientia Plc (EXAI)
Buy Rating Affirmed for Silence Therapeutics’ Divesiran Following Promising SANRECO Trial Results
Silence Therapeutics price target raised by $13 at Chardan, here's why
Silence Therapeutics price target raised by $4 at Morgan Stanley, here's why
Buy Rating Affirmed for Silence Therapeutics on Strong Divesiran Phase 1 Results and Positive Outlook